85 The diagnostic value of cell free DNA levels in prostate cancer and a reminder on the importance of sample selection

2004 ◽  
Vol 3 (2) ◽  
pp. 24
Author(s):  
J. Boddy ◽  
S. Gal ◽  
A. Harris ◽  
J. Wainscoat ◽  
P. Malone
Keyword(s):  
Prostate Cancer ◽  
Sample Selection ◽  
Diagnostic Value ◽  
Cell Free Dna ◽  
Free Dna

scholarly journals Quantitative and Qualitative Analysis of Circulating Cell-Free DNA Can Be Used as an Adjuvant Tool for Prostate Cancer Screening: A Meta-Analysis

2016 ◽  
Vol 2016 ◽  
pp. 1-12 ◽  
Author(s):  
Changqing Yin ◽  
Changliang Luo ◽  
Wei Hu ◽  
Xu Ding ◽  
Chunhui Yuan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Qualitative Analysis ◽  
Prostate Cancer Screening ◽  
Meta Analysis ◽  
Specific Antigen ◽  
Diagnostic Value ◽  
Qualitative Assessment ◽  
Cell Free Dna ◽  
Free Dna ◽  
Circulating Cell Free Dna

As part of “liquid biopsy,” lots of literature indicated the potential diagnostic value of circulating cell-free DNA (cfDNA) in the management of prostate cancer (PCa). However, the literature on the accuracy of cfDNA detection in PCa has been inconsistent. Hence, we performed this meta-analysis to assess the diagnostic value of cfDNA in PCa. A total of 19 articles were included in this analysis according to the inclusion and exclusion criteria. We then investigated two main subgroups in this meta-analysis, including qualitative analysis of abnormal level of cfDNA and qualitative analysis of single-gene methylation alterations. Overall, the results of quantitative analysis showed sensitivity of 0.73 (95% CI, 0.62–0.82) and specificity of 0.80 (95% CI, 0.70–0.87), with an area under the curve (AUC) of 0.83 (95% CI, 0.80–0.86). For qualitative assessment, the values were 0.34 (95% CI, 0.22–0.48), 0.99 (95% CI, 0.97–1.00), and 0.91 (95% CI, 0.88–0.93), respectively. Our results suggest the pooled specificity of each subgroup is much higher than the specificity of prostate-specific antigen (PSA). However, they are not recommended for PCa screening alone, because their sensitivities are not higher than the conventional serum biomarkers PSA. We conclude that analysis of cfDNA can be used as an adjuvant tool for PCa screening.

Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing

2021 ◽  
pp. 710-725
Author(s):  
Emmalyn Chen ◽  
Clinton L. Cario ◽  
Lancelote Leong ◽  
Karen Lopez ◽  
César P. Márquez ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tumor Tissue ◽  
Somatic Tissue ◽  
Localized Prostate Cancer ◽  
Genomic Alterations ◽  
Cell Free Dna ◽  
Free Dna ◽  
Multiple Regions ◽  
Localized Disease ◽  
Tissue Alterations

PURPOSE Cell-free DNA (cfDNA) may allow for minimally invasive identification of biologically relevant genomic alterations and genetically distinct tumor subclones. Although existing biomarkers may detect localized prostate cancer, additional strategies interrogating genomic heterogeneity are necessary for identifying and monitoring aggressive disease. In this study, we aimed to evaluate whether circulating tumor DNA can detect genomic alterations present in multiple regions of localized prostate tumor tissue. METHODS Low-pass whole-genome and targeted sequencing with a machine-learning guided 2.5-Mb targeted panel were used to identify single nucleotide variants, small insertions and deletions (indels), and copy-number alterations in cfDNA. The majority of this study focuses on the subset of 21 patients with localized disease, although 45 total individuals were evaluated, including 15 healthy controls and nine men with metastatic castration-resistant prostate cancer. Plasma cfDNA was barcoded with duplex unique molecular identifiers. For localized cases, matched tumor tissue was collected from multiple regions (one to nine samples per patient) for comparison. RESULTS Somatic tumor variants present in heterogeneous tumor foci from patients with localized disease were detected in cfDNA, and cfDNA mutational burden was found to track with disease severity. Somatic tissue alterations were identified in cfDNA, including nonsynonymous variants in FOXA1, PTEN, MED12, and ATM. Detection of these overlapping variants was associated with seminal vesicle invasion ( P = .019) and with the number of variants initially found in the matched tumor tissue samples ( P = .0005). CONCLUSION Our findings demonstrate the potential of targeted cfDNA sequencing to detect somatic tissue alterations in heterogeneous, localized prostate cancer, especially in a setting where matched tumor tissue may be unavailable (ie, active surveillance or treatment monitoring).

Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA

JAMA Oncology ◽  
2021 ◽  
Author(s):  
Michael T. Schweizer ◽  
Smruthy Sivakumar ◽  
Hanna Tukachinsky ◽  
Ilsa Coleman ◽  
Navonil De Sarkar ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Dna Repair ◽  
Gene Mutations ◽  
Repair Gene ◽  
Cell Free Dna ◽  
Metastatic Tissue ◽  
Free Dna ◽  
Primary Prostate Cancer ◽  
Dna Repair Gene

scholarly journals Assessing the Diagnostic Value of Plasma-Free DNA in Prostate Cancer Screening

2018 ◽  
Vol 22 (5) ◽  
pp. 331-337 ◽  
Author(s):  
Seyedeh Maryam Seyedolmohadessin ◽  
Mohammad Taghi Akbari ◽  
Zahra Nourmohammadi ◽  
Abbas Basiri ◽  
Gholamreza Pourmand ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Screening ◽  
Prostate Cancer Screening ◽  
Diagnostic Value ◽  
Free Dna

scholarly journals Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition

2017 ◽  
Vol 7 (9) ◽  
pp. 1006-1017 ◽  
Author(s):  
Jane Goodall ◽  
Joaquin Mateo ◽  
Wei Yuan ◽  
Helen Mossop ◽  
Nuria Porta ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Treatment ◽  
Parp Inhibition ◽  
Prostate Cancer Treatment ◽  
Cell Free Dna ◽  
Free Dna ◽  
Circulating Cell Free Dna

Clinical impact of detecting low-frequency variants in cell-free DNA on treatment of castration-resistant prostate cancer

2021 ◽  
pp. clincanres.2328.2021
Author(s):  
Kei Mizuno ◽  
Takayuki Sumiyoshi ◽  
Takatsugu Okegawa ◽  
Naoki Terada ◽  
Satoshi Ishitoya ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Low Frequency ◽  
Clinical Impact ◽  
Castration Resistant Prostate Cancer ◽  
Cell Free Dna ◽  
Castration Resistant ◽  
Free Dna

Impact Of Cell-Free Plasma DNA In Metastatic And Non-Metastatic Prostate Cancer

2021 ◽  
Vol 21 ◽  
Author(s):  
Abdelraouf A. Abonar ◽  
Shymaa E. Ayoub ◽  
Ibrahim A. Tagreda ◽  
Marwa N. Abdelhafez ◽  
Mohammed M Khamiss ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Metastatic Prostate Cancer ◽  
Plasma Dna ◽  
Cell Free Dna ◽  
Group Iii ◽  
Free Dna ◽  
Group I ◽  
Total Psa ◽  
Free Plasma

: Increased cell-free DNA (cfDNA) is observed in many diseases such as cancer, myocardial infarction, and autoimmune diseases. It has the ability to alter the receptor cell phenotype, triggering events related to malignant transformation. Our study aims at assessing the use of Cell-free plasma DNA in the diagnosis of metastatic and non-metastatic prostate cancer. The study included 180 subjects who were classified into four groups: Group I (GI) included 50 in perfect health subjects as the control group, Group II (GII) included 40 patients with prostatitis, group III (GIII) included 40 patients with benign prostatic hyperplasia (BPH) and Group IV (GIV) included 50 patients with pre-operative prostate cancer (PC). Evaluation of the plasma level of circulating cell-free DNA by real-time PCR and measurement of total PSA (tPSA) and free to total PSA percent (f/tPSA%) were done for all groups. Our study revealed that the level of tPSA was significantly higher in prostate cancer patients while levels of f/t PSA were found to be significantly lower. The level of cfDNA was significantly higher in prostate cancer patients (399.9±88.6ng/ul) when compared to that of the group I (12.1±1.5ng/ul) (p<0.01), group II (14.7±2.4 ng/ul) (p<0.01), and group III (26.6±45.6 ng/ul) (p<0.01) respectively. There was a statistically significant difference in yields of cfDNA between metastatic and non- metastatic groups (P=0.03) with a higher level in the metastatic group.

Sign in / Sign up

Export Citation Format

Share Document